Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL988264 | 0.98 | OPRM1 (0.42) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL169284 | 0.87 | — | — | |
| Hexane SCHEMBL3754301 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL7574727 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| Hexane SCHEMBL17747414 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| Heptane SCHEMBL15226631 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| Hexane SCHEMBL8102949 | 0.84 | TSHR (0.41) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL688498 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL154425 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL16969849 | 0.84 | TSHR (0.50) | OPRM1LMNADNM1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8765741-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2718273-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | Anadys Pharmaceuticals, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140066396-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2013171281-A1 | HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS | VIVALIS (FR) | 2013-11-21 | — | — | WO | disclosed |
| EP-2664616-A1 | Hydantoin and thiohydantoin derivatives as antiviral drugs | Vivalis (FR) | 2013-11-20 | — | — | EP | disclosed |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8101800-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2346329-A1 | A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7939524-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2010042834-A1 | A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2129224-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | OPRM1 721/4885LMNA 231/4885TP53 3491/4885 |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | OPRM1 1571/4885LMNA 1248/4885TP53 1144/4885 |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, HCCS | OPRM1 902/4885LMNA 700/4885TP53 2381/4885 |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | OPRM1 721/4885LMNA 231/4885TP53 3491/4885 |
| US-20140066396-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, HCCS | OPRM1 902/4885LMNA 700/4885TP53 2381/4885 |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, CCR3, C5 | OPRM1 2161/4885LMNA 1368/4885TP53 1008/4885 |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | OPRM1 1571/4885LMNA 1248/4885TP53 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.